Therefore, we performed flow cytometry analysis to examine the CD44/CD24 population in four different kinds of breast cancer cells (BT-549, MDA-MB-231, Hs-578T, and MCF-7 cells) 3 to 5 days after CRISPRMAX-PKAs delivery. The gene discussed is CD44; the disease is breast carcinoma.